Biofrontera AG signs distribution agreement for Ameluz with Propharma in Croatia
I'm PortAI, I can summarize articles.
Biofrontera AG has signed a distribution agreement with Propharma d.o.o. for the commercialization of Ameluz® in Croatia. Propharma will seek reimbursement for the product, with sales expected to begin by the end of 2026, pending successful reimbursement discussions. Ameluz® is used to treat mild to moderate actinic keratosis and superficial/nodular basal cell carcinoma in adults.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments